J. Tercero

发表

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

J. Blay, F. Grosso, A. Cesne, 2011, European journal of cancer.

Directed covalent immobilization of aminated DNA probes on aminated plates.

Manuel Fuentes, Roberto Fernández-Lafuente, R. Fernández-Lafuente, 2004, Biomacromolecules.

Detecting minimal traces of DNA using DNA covalently attached to superparamagnetic nanoparticles and direct PCR-ELISA.

R. Fernández-Lafuente, H. Riese, J. Tercero, 2006, Biosensors & bioelectronics.

Mutations in the rpoB Gene of Rifampin-Resistant Mycobacterium tuberculosis Isolates in Spain and Their Rapid Detection by PCR–Enzyme-Linked Immunosorbent Assay

J. Tercero, M. Rebollo, F. Chaves, 2001, Journal of Clinical Microbiology.

Journal of Translational Medicine BioMed Central Review

J. Tercero, J. Jimeno, M. Aracil, 2005 .

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

F. Grosso, P. Casali, S. Pilotti, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).

J. Lubiński, F. Holmes, S. Delaloge, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

W. Gregory, R. Gomis, F. Rojo, 2017, The Lancet. Oncology.

In vitro radiosensitisation by trabectedin in human cancer cell lines.

R. Sánchez-Prieto, J. Romero, J. Tercero, 2008, European journal of cancer.

16 a-[ 1251 ]-$-EstradiolComparedwith [ 3 H ]-f 3-Estradiolas the Tracer in EstradiotReceptorAssays

J. Tercero, J. Nelson, A. Broughton, 2004 .

Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors

F. Grosso, P. Casali, S. Pilotti, 2010, Clinical Cancer Research.

Inhibitory effects of marine‐derived DNA‐binding anti‐tumour tetrahydroisoquinolines on the Fanconi anaemia pathway

F. Gago, C. Galmarini, J. Bueren, 2013, British journal of pharmacology.

Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response

J. Benítez, A. Nieto, J. Tercero, 2013, Molecular Cancer Therapeutics.

Clinical Cancer esearch linical Therapy el Models of Myxoid Liposarcoma Xenografts Mimicking Biological and Pharmacologic Features of R an Tumors

S. Pilotti, A. Gronchi, M. D’Incalci, 2010 .

Characterization of a new trabectedin‐resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

M. Rocchi, O. Capozzi, F. Grosso, 2012, International journal of cancer.

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

J. Vaquero, F. Gago, E. Marco, 2008, Molecular Cancer Therapeutics.

Levels of p27kip1 determine Aplidin sensitivity

J. Leal, A. Carnero, C. Blanco-Aparicio, 2007, Molecular Cancer Therapeutics.

Fractionation of plasmic fibrin(ogen) digests by lectin affinity chromatography.

J. Tercero, D. Solís, T. Díaz-Mauriño, 1989, Thrombosis research.

Affinity chromatography of fibrinogen on Lens culinaris agglutinin immobilized on CNBr-activated sepharose: study of the active groups involved in nonspecific adsorption.

J. Tercero, T. Díaz-Mauriño, 1988, Analytical biochemistry.

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients

M. Piris, M. Sánchez-Beato, A. Carnero, 2005, Molecular Cancer Therapeutics.

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Robin L. Jones, J. Blay, J. Fletcher, 2007, The Lancet. Oncology.

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

J. Blay, G. Demetri, B. Bui, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

P. Allavena, A. Mantovani, F. Grosso, 2010, Cancer research.

DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743).

J. Blay, F. Grosso, R. Maki, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis

A. Carnero, C. Blanco-Aparicio, R. Díaz-Uriarte, 2014, BMC Cancer.

Changes in pH associated with clotting of fibrinogen. Kinetic studies of the pH shift and correlation of the pH change with the release of fibrinopeptides and the ensuing polymerization.

J. Tercero, E. Mihályi, T. Díaz-Mauriño, 1991, Biochemistry.

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.

B. Monk, S. Kaye, C. Lebedinsky, 2011, Gynecologic oncology.

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

J. Blay, B. Bui, J. Coindre, 2011, Cancer.

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

C. Wilson, W. Gregory, R. Gomis, 2018, Journal of bone oncology.

Dexamethasone attenuates the embryotoxic effect of endometriotic peritoneal fluid in a murine model

J. Tercero, R. Burney, R. Heitmann, 2015, Journal of Assisted Reproduction and Genetics.

A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).

J. Lubiński, F. Holmes, S. Delaloge, 2010 .

Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

J. Cigudosa, M. Piris, M. Sánchez-Beato, 2007, Journal of cellular biochemistry.

479 Impact of the DNA repair efficiency in the outcome of sarcoma patients treated with ET-743 (Yondelis)

R. Sciot, R. Maki, R. Rosell, 2004 .

MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

R. Gomis, N. Wolmark, A. Wolff, 2021, JNCI cancer spectrum.

Trabectedin (T) in advanced, pretreated synovial sarcomas (SS): A retrospective analysis of 39 patients (pts) from three European institutions.

J. Blay, F. Grosso, A. Cesne, 2010 .

Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).

J. Lubiński, F. Holmes, S. Delaloge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rechallenge with trabectedin in patients with responding myxoid liposarcoma.

F. Grosso, P. Casali, S. Pilotti, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM).

F. Grosso, P. Casali, I. Judson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simple and rapid detection of Mycobacterium tuberculosis complex organisms in bovine tissue samples by PCR

J. Tercero, M. Domingo, E. Liébana, 1995, Journal of clinical microbiology.

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

D. Dodwell, R. Bell, M. Keane, 2018, Journal of bone oncology.